Center-Authored Papers

Filters: Author is Chansky, Kari  [Clear All Filters]
2008
Sculier J-P, Chansky K, Crowley J, Van Meerbeeck J, Goldstraw P.  2008.  The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 3(5):457-66. Abstract
Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DHM, Crowley J, Gandara DR.  2008.  Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(15):2450-6. Abstract
Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le Q-T, Crowley J, Gandara DR.  2008.  Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(29):4771-6. Abstract
Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley J et al..  2008.  Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 3(9):1026-31. Abstract
2009
Davies AM, Chansky K, Lara PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR.  2009.  Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 4(1):87-92. Abstract
Chansky K, Sculier J-P, Crowley J, Giroux D, Van Meerbeeck J, Goldstraw P.  2009.  The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 4(7):792-801. Abstract
Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler PJ, Dakhil SR et al..  2009.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2530-5. Abstract
Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P.  2009.  The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 4(9):1049-59. Abstract
2010
Pisters KMW, Vallières E, Crowley J, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D.  2010.  Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(11):1843-9. Abstract
Chansky K, Sculier J-P, Crowley J, Giroux D, Van Meerbeeck J, Goldstraw P.  2010.  [The International Association for the Study of Lung Cancer Staging Project. Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer].. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 13(1):9-18.
Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES et al..  2010.  Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(31):4747-54. Abstract
2011
Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, Redman MW, Gandara DR.  2011.  Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 6(11):1938-45. Abstract
2014
Philip PA, Chansky K, Rubinstein L, LeBlanc M, Seymour L, Ivy PS, Alberts SR, Catalano PJ, Crowley J.  2014.  Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single Arm Phase II Trials.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, Goldstraw P.  2014.  The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 9(11):1618-24. Abstract
2016
Johnson BA, Long Q, Huang Y, Chansky K, Redman M.  2016.  Model selection and inference for censored lifetime medical expenditures.. Biometrics. 72(3):731-741. Abstract